Geldanamycin mediates the apoptosis of gastric carcinoma cells through inhibition of EphA2 protein expression

Oncology Reports

Volumn 32, Issue 6, 2014, Pages 2429-2436

  Wang, Da Hu ^a   Zhang, Yu Jun ^b   Zhang, San Bing ^c   Liu, Hui ^a   Liu, Liang ^a   Liu, Feng Ling ^a   Zuo, Jing ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b Department of Pathology   (China)

^c Third Hospital of Shijiazhuang   (China)

Author keywords

Apoptosis; Cell proliferation; EphA2; Gastric carcinoma; Geldanamycin; MGC803 cell line

Indexed keywords

EPHRIN A2; GELDANAMYCIN; MESSENGER RNA; ANTINEOPLASTIC ANTIBIOTIC; BENZOQUINONE DERIVATIVE; EPHRIN RECEPTOR A2; MACROCYCLIC LACTAM;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; PROTEIN FUNCTION; STOMACH CARCINOGENESIS; STOMACH CARCINOMA; STOMACH EPITHELIUM; STOMACH MUCOSA; CARCINOMA; CELL CYCLE; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; SECONDARY; STOMACH NEOPLASMS; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BENZOQUINONES; CARCINOMA; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; LACTAMS, MACROCYCLIC; LYMPHATIC METASTASIS; RECEPTOR, EPHA2; STOMACH NEOPLASMS;

EID: 84914670351     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3542     Document Type: Article

References (27)

1. Nakamoto M and Bergemann AD: Diverse roles for Eph family of receptor tyrosine kinases in carcinogenesis. Microsc Res Tech 59: 58-67, 2002.
2. Fang WB, Brantley-Sieders DM, Parker MA, Reith AD and Chen J: A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis. Oncogene 24: 7859-7868, 2005
3. Miyazaki T, Kato H, Fukuchi M, Nakajima M and Kuwano H: EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int J Cancer 103: 657-663, 2003.
4. Orsulic S and Kemler R: Expression of Eph receptors and ephrins is differentially regulated by E-cadherin. J Cell Sci 113: 1793-1802, 2000.
5. Trojandt S, Reske-Kunz AB and Bros M: Geldanamycin-mediated inhibition of heat shock protein 90 partially activates dendritic cells, but interferes with their full maturation, accompanied by impaired upregulation of Relb. J Exp Clin Cancer Res 33: e16, 2014
6. Zeng G, Hu Z, Kinch MS, Pan CX, Flockhart DA, Kao C, Gardner TA, Zhang S, Li L, Baldridge LA, Koch MO, Ulbright TM, Eble JN and Cheng L: High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Patho 1163: 2271-2276, 2003.
7. Feng X, Hao J, Liu Q, Yang L, Lv X, Zhang Y, Xing L, Xu N and Liu S: HMGb1 mediates IFN-γ-induced cell proliferation in MMC cells through regulation of cyclin D1/CDK4/p16 pathway. J Cell Biochem 113: 2009-2019, 2012.
8. Hao J, Zhang YJ, Lv X, Xu N, Liu QJ, Zhao S, Feng XJ, Xing LL, Kang PP, Li GY and Liu SX: IFN-γ induces lipogenesis in mouse mesangial cells via the jAK2/STAT1 pathway. Am J Physiol Cell Physiol 304: c760-c767, 2013.
9. Dodelet VC and Pasquale EB: Eph receptors and ephrin ligands: embryogenesis to tumorigenesis. Oncogene 19: 5614-5619, 2000.
10. Duxbury MS, Ito H, Zinner MJ, Ashley SW and Whang EE: Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adeno-carcinoma cellular invasiveness. Biochem Biophys Res Commun 320: 1096-1102, 2004.
11. Thaker PH, Deavers M, Celestino J, Thornton A, Fletcher MS, Landen CN, Kinch MS, Kiener PA and Sood AK: EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res 10: 5145-5150, 2004.
12. Wykosky J, Gibo DM, Stanton C and Debinski W: EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol Cancer Res 3: 541-551, 2005.
13. Liu F, Park PJ, Lai W, Maher E, Chakravarti A, Durso L, Jiang X, Yu Y, Brosius A, Thomas M, Chin L, Brennan C, DePinho RA, Kohane I, Carroll RS, Black PM and Johnson MD: A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA2 as a mitogen in glioblastoma. Cancer Res 66: 10815-10823, 2006.
14. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR and Kinch MS: EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 61: 2301-2306, 2001.
15. Hess AR, Seftor EA, Gruman LM, Kinch MS, Seftor RE and Hendrix MJ: VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry. Cancer Biol Ther 5: 228-233, 2006.
16. Brantley-Sieders DM, Zhuang G, Hicks D, Fang WB, Hwang Y, Cates JM, Coffman K, Jackson D, Bruckheimer E, Muraoka-Cook RS and Chen J: The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying Erbb2 signaling. J Clin Invest 118: 64-78, 2008.
17. Fox BP and Kandpal RP: Invasiveness of breast carcinoma cells and transcript profile: Eph receptors and ephrin ligands as molecular markers of potential diagnostic and prognostic application. Biochem Biophys Res Commun 318: 882-892, 2004.
18. Herrem CJ, Tatsumi T, Olson KS, Shirai K, Finke JH, Bukowski RM, Zhou M, Richmond AL, Derweesh I, Kinch MS and Storkus WJ: Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. Clin Cancer Res 11: 226-231, 2005.
19. Merritt WM, Thaker PH, Landen CN JR, Deavers MT, Fletcher MS, Lin YG, Han LY, Kamat AA, Schmandt R, Gershenson DM, Kinch MS and Sood AK: Analysis of EphA2 expression and mutant p53 in ovarian carcinoma. Cancer Biol Ther 5: 1357-1360, 2006.
20. Abraham S, Knapp DW, Cheng L, Snyder PW, Mittal SK, Bangari DS, Kinch M, Wu L, Dhariwal J and Mohammed SI: Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Clin Cancer Res 12: 353-360, 2006.
21. Larsen AB, Pedersen MW, Stockhausen MT, Grandal MV, van Deurs B and Poulsen HS: Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility. Mol Cancer Res 5: 283-293, 2007.
22. Fang WB, Brantley-Sieders DM, Parker MA, Reith AD and Chen J: A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis. Oncogene 24: 7859-7868, 2005.
23. Carles-Kinch K, Kilpatrick KE, Stewart JC and Kinch MS: Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res 62: 2840-2847, 2002.
24. Zantek ND, Azimi M, Fedor-Chaiken M, Wang B, Brackenbury R and Kinch MS: E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell Growth Differ 10: 629-638, 1999.
25. Macrae M, Neve RM, Rodriguez-Viciana P, Haqq C, Yeh J, Chen C, Gray JW and McCormick F: A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell 8: 111-118, 2005.
26. Ui T, Morishima K, Saito S, Sakuma Y, Fujii H, Hosoya Y, Ishikawa S, Aburatani H, Fukayama M, Niki T and Yasuda Y: The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal squamous cell carcinoma cell lines via the Akt/XIAP pathway. Oncol Rep 31: 619-24, 2014.
27. Jilani K, Qadri SM and Lang F: Geldanamycin-induced phos-phatidylserine translocation in the erythrocyte membrane. Cell Physiol Biochem 32: 1600-1609, 2013.